CBI exodus: Which firms have quit or suspended their relationship with the lobby group? April 21, 2023 A slew of top firms have quit or suspended engagement with the CBI today after the lobby group was rocked by new allegations of sexual abuse.
AstraZeneca: UK-Swedish pharma giant almost doubled exports to Russia after invasion of Ukraine March 7, 2023 Anglo-Swedish drugs giant AstraZeneca nearly doubled its exports from Sweden to Russia after the Kremlin launched its full-scale attack on Ukraine, according to a report. Sveriges Radio (SR) – the country’s public service broadcaster – said that the FTSE 100 company had exported 2.2 billion Swedish krona (£174 million) worth of chemicals to Russia from [...]
UK lost out on £320m AstraZeneca factory: Hunt ‘disappointed’ after drug giant choses low-tax Ireland instead February 10, 2023 Chancellor Jeremy Hunt said he was disappointed the UK “lost out this time” on a £320 million new AstraZeneca factory after the drugs giant chose the low-tax Republic of Ireland instead. The group had wanted to build a plant near its existing sites close to Macclesfield, Cheshire, but the “discouraging” tax rate had prompted a [...]
Astrazeneca’s shares rise, as cancer drug uptake offsets fall in sales of pharma giant’s Covid-19 vaccine February 9, 2023 Astrazeneca has posted what it claimed were “strong” financial results for the full year 2022 as surging demand for cancer medicines offset a fall in Covid vaccine revenues. Shares in Astrazeneca jumped on the news as the firm said it expects another year of double-digit revenue growth in 2023. The British firm’s strong results came [...]
Drug developer files patents for cancer treatment which ‘outperforms’ AstraZeneca offering December 20, 2022 Drug development company Nuformix has reformulated and improved one of AstraZeneca’s top cancer drugs, piquing investor interest today. Shares in the London-listed firm jumped nearly a quarter to 35p per share by early afternoon on Tuesday. Nuformix, which focuses on fibrosis and cancer drug repurposing, announced that the drug, known as Olaparib, had “outperformed” AstraZeneca’s [...]
European regulator injects hope into AstraZeneca’s bid to tackle cancer December 19, 2022 The European Medicines Agency has handed AstraZeneca a number of recommendations and one approval for a trio of cancer drugs the Big Pharma firm is looking to market in the continent. AstraZeneca’s cancer drug Enhertu has been given the green light by the European regulator for use among patients with gastric cancer. Around 136,000 cases [...]
AstraZeneca buys therapy firm Neogene for £266m in latest bid to tackle cancer November 29, 2022 AstraZeneca has bought cancer cell therapy company Neogene Therapeutics for $320m (£266m), in the company’s latest investment in its oncology offering. The deal, which is set to close in the coming months, will see AstraZeneca pay $200m as cash in hand, and another $120m if Neogene meets certain milestones. The British-Swedish pharmaceutical giant, behind one [...]
Drug developer C4X shares fly after signing £330m AstraZeneca licensing deal November 28, 2022 Drug developer C4X Discovery has signed an exclusive licensing agreement worth up to $402m (£334m) with pharma giant AstraZeneca to develop oral therapy to treat inflammatory diseases. London-listed C4XD’s shares have rocketed this morning, up nearly 40 per cent to 28.5p so far. As part of the deal, C4XD will receive pre-clinical milestone payments worth up [...]
AstraZeneca’s battle against cancer knocks on door of EU with three new drugs November 14, 2022 AstraZeneca, the pharmaceutical giant behind one of the world’s first Covid-19 vaccines, has had three new cancer drugs recommended for approval in the European Union. The FTSE 100 pharma firm said its drug Imfinzi – for uses against biliary tract cancer alongside chemotherapy, gastric cancer medicine Enhertu and prostate cancer treatment Lynparza, in combination with [...]
AstraZeneca boss urges UK government to invest in medicines of the future November 10, 2022 The chief of AstraZeneca has urged the UK government to invest in the medicines of the future, as the regulatory environment for pharma in the US grows tougher. With the UK’s upcoming budget, CEO Pascal Soriot called on the government to protect the funding for innovative treatments as the long-term outlook for the healthcare industry [...]